{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:01:11Z","timestamp":1760058071711,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Fibrosing interstitial lung diseases can evolve into acute exacerbations, which significantly impact morbidity and mortality. Currently, no routinely used clinical biomarkers can discern the potential progression in these patients. This study aims to analyze different biological markers used in routine clinical practice as possible predictive biomarkers for patients with acute fibrosing interstitial lung disease exacerbation. Methods: We conducted a retrospective, single-center study including patients diagnosed with acute exacerbation of fibrosing interstitial lung disease who required hospitalization between 2018 and 2019 at Vall d\u2019Hebron Hospital, Spain. Patient demographics, clinical data, respiratory function, and comorbidities were collected at baseline. The primary outcome was survival at 30 days, 90 days, and 365 days, using Kaplan\u2013Meier survival analysis and Cox regression. Results: Twenty-nine patients were included (mean age 70.4 years). At the 3-month follow-up, patients with ischemic heart disease showed higher survival rates (p = 0.02). Identifying an infection as the etiology of the exacerbation was associated with worse one-year survival rates compared to idiopathic cases (p = 0.03). Elevated levels of leukocytes (p &lt; 0.01), neutrophils (p &lt; 0.01), and fibrinogen (p = 0.03) were predictors of mortality. Additionally, patients who received a cumulative dose of corticosteroids between 501 and 1000 mg during the exacerbation showed higher one-year survival (p &lt; 0.01). Conclusions: Routine clinical markers can help predict outcomes in AE-f-ILD. Further multicenter studies should validate these findings and assess the role of therapies in its management.<\/jats:p>","DOI":"10.3390\/jcm14061974","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:02:16Z","timestamp":1741935736000},"page":"1974","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Analysis of Predictive Biomarkers of Survival in Acute Exacerbation of Fibrosing Interstitial Lung Disease: A Single-Center Study in Spain"],"prefix":"10.3390","volume":"14","author":[{"given":"Ant\u00eda","family":"Ferreiro-Posse","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1902-1835","authenticated-orcid":false,"given":"Galo","family":"Granados","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Salvador","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2880-4019","authenticated-orcid":false,"given":"Maria Florencia","family":"Pilia","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Espejo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8806-3908","authenticated-orcid":false,"given":"Ana","family":"Villar","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University Hospital Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"},{"name":"Spanish Biomedical Research Networking Centre (CIBERES), Carlos III Health Research Institute, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"ILD working group. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: Knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.resinv.2022.03.004","article-title":"Current perspective of progressive-fibrosing interstitial lung disease","volume":"60","author":"Kishaba","year":"2022","journal-title":"Respir. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccm.2021.03.008","article-title":"Diagnosis and Management of Fibrotic Interstitial Lung Diseases","volume":"42","author":"Collins","year":"2021","journal-title":"Clin. Chest Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/resp.14245","article-title":"Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype","volume":"27","author":"Takei","year":"2022","journal-title":"Respirology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","article-title":"Progressive fibrosing interstitial lung disease: Prevalence and clinical outcome","volume":"22","author":"Kwon","year":"2021","journal-title":"Respir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Leuschner, G., and Behr, J. (2017). Acute Exacerbation in Interstitial Lung Disease. Front. Med., 3.","DOI":"10.3389\/fmed.2017.00176"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12931-021-01748-2","article-title":"Acute exacerbation of fibrotic hypersensitivity pneumonitis: Incidence and outcomes","volume":"22","author":"Kang","year":"2021","journal-title":"Respir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"180071","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1159\/000533312","article-title":"Acute Exacerbation and Proposed Criteria for Progressive Pulmonary Fibrosis in Patients with Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis","volume":"102","author":"Okuda","year":"2023","journal-title":"Respiration"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute Exacerbations of Idiopathic Pulmonary Fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"170050","DOI":"10.1183\/16000617.0050-2017","article-title":"Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis","volume":"26","author":"Kondoh","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-020-1296-3","article-title":"Progression of fibrosing interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s12325-019-00992-9","article-title":"Management of Fibrosing Interstitial Lung Diseases","volume":"36","author":"Maher","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2014An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12931-023-02614-z","article-title":"Clinical impact of pre-existing acute exacerbation in patients with interstitial lung disease who underwent lung transplantation","volume":"24","author":"Kim","year":"2023","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Huang, T.H., Kuo, C.W., Chen, C.W., Tseng, Y.L., Wu, C.L., and Lin, S.H. (2021). Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: A retrospective real-world cohort study. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01530-6"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2101181","DOI":"10.1183\/13993003.01181-2021","article-title":"Biomarker signatures for progressive idiopathic pulmonary fibrosis","volume":"59","author":"Clynick","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Caliskan, C., Seeliger, B., J\u00e4ger, B., Fuge, J., Welte, T., Terwolbeck, O., Freise, J., van Moorsel, C.H.M., Zhang, Y., and Prasse, A. (2020). Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis\u2014Part B. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061993"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Majewski, S., Szewczyk, K., Jerczy\u0144ska, H., Mi\u0142kowska-Dymanowska, J., Bia\u0142as, A.J., Gwadera, \u0141., and Piotrowski, W.J. (2022). Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients with Idiopathic Pulmonary Fibrosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.760776"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00134-012-2682-1","article-title":"The Berlin definition of ARDS: An expanded rationale, justification, and supplementary material","volume":"38","author":"Ferguson","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Markin, A.M., Markina, Y.V., Bogatyreva, A.I., Tolstik, T.V., Chakal, D.A., Breshenkov, D.G., and Charchyan, E.R. (2023). The Role of Cytokines in Cholesterol Accumulation in Cells and Atherosclerosis Progression. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076426"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.amjcard.2015.05.028","article-title":"Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events","volume":"116","author":"Cangemi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2014.07.985","article-title":"Platelet Activation Is Associated with Myocardial Infarction in Patients with Pneumonia","volume":"64","author":"Cangemi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.jacc.2014.08.023","article-title":"The Sum of Two Evils","volume":"64","author":"Badimon","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41479-016-0011-0","article-title":"Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia","volume":"8","author":"Feldman","year":"2016","journal-title":"Pneumonia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0049-3848(00)00237-1","article-title":"Relevance of Tissue Factor and Tissue Factor Pathway Inhibitor for Hypercoagulable State in the Lungs of Patients with Idiopathic Pulmonary Fibrosis","volume":"99","author":"Fujii","year":"2000","journal-title":"Throm. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0049-3848(95)00025-9","article-title":"Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis","volume":"77","author":"Kotani","year":"1995","journal-title":"Throm. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/thx.2009.119974","article-title":"Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis","volume":"65","author":"Senoo","year":"2010","journal-title":"Thorax"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.chest.2020.10.019","article-title":"Association between Anticoagulation and Survival in Interstitial Lung Disease","volume":"159","author":"King","year":"2021","journal-title":"Chest"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1183\/16000617.00008414","article-title":"Coagulation and anticoagulation in idiopathic pulmonary fibrosis","volume":"24","author":"Crooks","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13515","article-title":"Aspirin use is associated with lower liver fibrosis indices among adults in the United States","volume":"43","author":"Jiang","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105744","DOI":"10.1016\/j.phrs.2021.105744","article-title":"Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained","volume":"170","author":"Tacconelli","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_40","first-page":"1351","article-title":"Aspirin inhibits endometrial fibrosis by suppressing theTGF-\u03b21-Smad2\/Smad3 pathway in intrauterine adhesions","volume":"45","author":"Zhang","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1074\/jbc.M109.029637","article-title":"Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite Phosphorylation","volume":"285","author":"Foster","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112085","DOI":"10.1016\/j.exger.2023.112085","article-title":"Aspirin alleviates pulmonary fibrosis through the PI3K\/AKT\/mTOR-mediated autophagy pathway","volume":"172","author":"Peng","year":"2023","journal-title":"Exp. Geront."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/jim-2021-002161","article-title":"Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside","volume":"70","author":"Amratia","year":"2022","journal-title":"J. Investig. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of Fibrotic Lung Diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1974\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:47Z","timestamp":1760028827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061974"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061974","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}